Compares two screening methods for liver cancer in people with cirrhosis or hepatitis B
Compares ultrasound and blood tests for liver cancer screening in people with liver disease.
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Ann Arbor, Boston, Chapel Hill, Chicago, Cleveland, Dallas, Detroit, Houston, Indianapolis, Los Angeles, Manhasset, Minneapolis, Philadelphia, Redwood City, Richmond, Roseville, and San Francisco, United StatesSee the 19 sites
- Trial code
- Registry title
- National Liver Cancer Screening Trial
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 5,500 people, planned
- Started
- 26 Dec 2023
- Expected to end
- 31 Dec 2034
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- GALAD
- Liver Ultrasound with or without AFP
- Record updated
- 25 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis from any cause, or with chronic hepatitis B, who need regular liver cancer screening. It compares two screening methods.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- Cirrhosis from any cause (not Child Pugh C), or chronic hepatitis B with a PAGE-B score greater than 9 within 12 months of enrollment.
- Earlier treatment
- No solid organ transplant. Not actively listed for liver transplant. No TIPS (transjugular intrahepatic portosystemic shunt).
- Biomarker or test result
- AFP must not be above 20 ng/mL within 6 months before consent, unless a contrast-enhanced CT or MRI shows no suspicious liver lesions.
Main reasons for not taking part
- Child Pugh C cirrhosis
- History or symptoms of liver cancer (hepatocellular carcinoma) or bile duct cancer (cholangiocarcinoma)
- Another active cancer, apart from non-melanomatous skin cancer or slow cancer under active surveillance, in the last 2 years
- Known pregnancy at consent
- Active warfarin use
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Patient must meet all of the following inclusion criteria:
- Adult patients ages 18-85 with cirrhosis from any etiology or with chronic hepatitis B with a PAGE-B score greater than 9 within 12 months of enrollment
- Patient is eligible for HCC surveillance according to treating physician or by the site investigator
- Able to provide informed consent
- Life expectancy >6 months (after consent) as determined by the treating provider or site investigator
Who cannot take part
- History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic CT/MRI demonstrating benign nature)
- AFP >20 ng/mL within 6 months prior to consent, in the absence of a contrast-enhanced CT or MRI within 6 months of AFP (before or after) level demonstrating lack of suspicious liver lesions
- Newly diagnosed LR-3 greater than or equal to 1 cm within 6 months prior to consent
- History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI within 6 months prior to consent
- Presence of another active cancer besides non-melanomatous skin cancer or indolent cancer under active surveillance (e.g., prostate cancer or renal cell carcinoma) within the 2 years prior to consent
- Actively listed for liver transplantation
- Diagnosis of alcohol-associated hepatitis within 3 months prior to consent
- In patients with primary sclerosing cholangitis (PSC): Current active cholangitis within 90 days prior to consent
- Known or documented habitual non-adherence to previous research studies or medical procedures or unwillingness to adhere to protocol (e.g., unwilling to obtain consent or samples)
- History of a transjugular intrahepatic portosystemic shunt (TIPS)
- History of Fontan associated liver disease or cardiac cirrhosis
- History of solid organ transplantation
- Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis)
- In patients living with HIV: CD4+ T cell count less than 100 cells/mm3 within 60 days prior to consent
- Patient will be excluded for any of the following exclusion criteria:
- Child Pugh C cirrhosis
- History or clinical symptoms of hepatocellular carcinoma or cholangiocarcinoma
- Patient's provider is planning to use MRI- or CT- based surveillance moving forward
- Known pregnancy at consent
- Active warfarin use
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Shay RobisonTaking people
- Massachusetts General HospitalBoston, United StatesContact: Megan MichtaTaking people
- University of North CarolinaChapel Hill, United StatesContact: Andrew Moon, MDTaking people
- Northwestern UniversityChicago, United StatesContact: Laura Kulik, MDTaking people
- The Cleveland ClinicCleveland, United StatesContact: Taebin SonTaking people
- Case Western Reserve UniversityCleveland, United StatesContact: Amit Singal, MD, MSNo longer taking part
- UT Southwestern Medical Center and Parkland HospitalDallas, United StatesContact: Katharine McCallisterTaking people
- Henry Ford Health SystemDetroit, United StatesContact: Jessica PeruskiTaking people
- Baylor College of MedicineHouston, United StatesContact: Emad SorialTaking people
- Indiana UniversityIndianapolis, United StatesContact: Sherri CumminsTaking people
- University of Southern CaliforniaLos Angeles, United StatesContact: Kali Zhou, MDTaking people
- The Feinstein Institutes, Northwell Health, Inc.Manhasset, United StatesContact: Dibnain NandaTaking people
- Hennepin HealthcareMinneapolis, United StatesContact: Jose Debes, MDTaking people
- University of MinnesotaMinneapolis, United StatesContact: Elizabeth Aby, MDTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Grace KimTaking people
- Stanford UniversityRedwood City, United StatesContact: Paul Kwo, MDTaking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Hannah Lee, MDTaking people
- Kaiser PermanenteRoseville, United StatesContact: Sreepriya Balasubramanian, MD, MPHTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Rae DavisTaking people
About the trial
What the trial wants to find out
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.
The 2 groups in the trial
- Arm A: Semi-annual surveillance using liver ultrasound +/- alpha-fetoproteinExisting treatment, for comparison
Participants in this arm will undergo current standard of care surveillance procedures i.e. liver ultrasound with or without alpha fetoprotein (AFP) measurement.
Treatment: Liver Ultrasound with or without AFP
- Arm B: Semi-annual surveillance using GALADTreatment being tested
For participants in this arm, study team will order GALAD measurement every 6 months +/- 3 months.
Treatment: GALAD
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- National Liver Cancer Screening Trial
- Plain-language title
- Compares two screening methods for liver cancer in people with cirrhosis or hepatitis BGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06084234, who can take part
- Publications
- National Liver Cancer Screening Trial (TRACER) study protocol.Hepatology communications, 2024
- Record updated
- 25 September 2026